UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 126

Sortiert nach

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Cancer cell, 2013-09, Vol.24 (3), p.289-304

2013

Link zum Volltext

Verfügbarkeit prüfen

sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution

Briefings in bioinformatics, 2022-01, Vol.23 (1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (3), p.757-768

2012

Link zum Volltext

Verfügbarkeit prüfen

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma

Cancer research (Chicago, Ill.), 2019-11, Vol.79 (21), p.5536-5549

2019

Link zum Volltext

Verfügbarkeit prüfen

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

Blood, 2007-06, Vol.109 (12), p.5430-5438

2007

Link zum Volltext

Verfügbarkeit prüfen

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma

Clinical cancer research, 2021-10, Vol.27 (19), p.5401-5414

2021

Link zum Volltext

Verfügbarkeit prüfen

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

Bone marrow transplantation (Basingstoke), 2020-03, Vol.55 (3), p.578-585

2020

Link zum Volltext

Verfügbarkeit prüfen

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

Cancer cell, 2008-02, Vol.13 (2), p.167-180

2008

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Characterization of 4‑Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma

Journal of medicinal chemistry, 2021-08, Vol.64 (15), p.11129-11147

2021

Link zum Volltext

Verfügbarkeit prüfen

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Cancer cell, 2015-10, Vol.28 (4), p.541-542

2015

Link zum Volltext

Verfügbarkeit prüfen

Correction to “Design, Synthesis, and Characterization of 4‑Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma”

Journal of medicinal chemistry, 2022-01, Vol.65 (1), p.886-887

2022

Link zum Volltext

Verfügbarkeit prüfen

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Blood, 2011-04, Vol.117 (14), p.3847-3857

2011

Link zum Volltext

Verfügbarkeit prüfen

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Blood, 2010-02, Vol.115 (8), p.1594-1604

2010

Link zum Volltext

Verfügbarkeit prüfen

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

JAMA oncology, 2020-02, Vol.6 (2), p.293

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo

Blood, 2009-04, Vol.113 (17), p.4027-4037

2009

Link zum Volltext

Verfügbarkeit prüfen

Getting to the root of the problem: the causes of relapse in multiple myeloma

Expert review of anticancer therapy, 2014-03, Vol.14 (3), p.251-254

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults

British journal of haematology, 2015-08, Vol.170 (3), p.384-390

2015

Link zum Volltext

Verfügbarkeit prüfen

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

The Journal of clinical investigation, 2008-05, Vol.118 (5), p.1750-1764

2008

Link zum Volltext

Verfügbarkeit prüfen

Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma

Cell reports (Cambridge), , Vol.25 (5), p.1318-1331.e4

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA06: Intratumor heterogeneity and its role in therapeutic escape in multiple myeloma

Clinical cancer research, 2017-12, Vol.23 (24_Supplement), p.IA06-IA06

Tiedemann, Rodger E.

2017

Link zum Volltext

Verfügbarkeit prüfen

OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S7-S7

2021

Link zum Volltext

Verfügbarkeit prüfen

Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2021-06, Vol.21 (6), p.e506-e509

2021

Link zum Volltext

Verfügbarkeit prüfen

OA-25 MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S15-S16

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15, p.S225-S226

2015

Link zum Volltext

Verfügbarkeit prüfen

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.1837-1837

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(125)
Berichte
(1)

Sprache

Englisch
(126)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Humans
(40)
Hematology
(27)
Oncology
(24)
Multiple Myeloma - Drug Therapy
(22)
Multiple Myeloma
(19)
Female
(17)
Middle Aged
(17)
Male
(16)
Multiple Myeloma - Pathology
(15)
Treatment Outcome
(15)
Adult
(14)
Aged
(13)
Bortezomib
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Animals
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Hematologic And Hematopoietic Diseases
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

Design, Synthesis, and Characterization of 4‑Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

Correction to “Design, Synthesis, and Characterization of 4‑Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma”

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6

Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-κB with antimyeloma activity in vitro and in vivo

Getting to the root of the problem: the causes of relapse in multiple myeloma

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma

Abstract IA06: Intratumor heterogeneity and its role in therapeutic escape in multiple myeloma

OAB-010: Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers

Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma

OA-25 MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

Suchergebnisse filtern